Flag of the European Union EU Clinical Trials Register Help

Clinical trials for exercise and diet intervention

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44393   clinical trials with a EudraCT protocol, of which   7405   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    25 result(s) found for: exercise and diet intervention. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2020-001069-35 Sponsor Protocol Number: IIBSP-EDA-2020-18 Start Date*: 2021-07-06
    Sponsor Name:Institut de Recerca de l’Hospital de la Santa Creu i Sant Pau – IIB Sant Pau
    Full Title: Impact of Exercise and Mediterranean diet vs Aspirin on live-birth rate and cardiovascular programming in In Vitro Fertilization (MEDITATE-IVF): a Randomized Study.
    Medical condition: Cumulative live-birth rate.
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-022897-14 Sponsor Protocol Number: PreMENAC-2011-01 Start Date*: 2011-05-02
    Sponsor Name:Dep. of Cancer Research and Molecular medicine, Norwegian University of Science and Technology
    Full Title: PreMENAC: Multimodal Exercise/Nutrition/Anti-inflammatory treatment for Cachexia: A feasibility study (phase II)
    Medical condition: Diagnosis of non operable non-small cell lung cancer NSCLC (stage III-IV) or pancreatic cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed) GB (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2005-001670-27 Sponsor Protocol Number: CSO1 Start Date*: 2005-11-14
    Sponsor Name:Greater Glasgow NHS Health Board / University of Glasgow co-sponsorship
    Full Title: Reversibility of cerebrovascular endothelial dysfunction in diabetes: the role of allopurinol.
    Medical condition: Type Two Diabetes Mellitus
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-004848-31 Sponsor Protocol Number: P04039 Start Date*: 2006-01-31
    Sponsor Name:SCHERING-PLOUGH
    Full Title: A Multicenter, Randomized, Parallel-Groups, Double-Blind Placebo Controlled Study Comparing The Efficacy, Safety, And Tolerability Of Administration Of Ezetimibe/Simvastatin tablet 10/20 Mg Versus ...
    Medical condition: Hypercholesterolemia
    Disease: Version SOC Term Classification Code Term Level
    6.1 10020603 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-004830-14 Sponsor Protocol Number: UX007-CL201 Start Date*: 2014-02-26
    Sponsor Name:Ultragenyx Pharmaceutical Inc.
    Full Title: An Open-Label Phase 2 Study to Assess Safety and Clinical Effects of UX007 in Subjects with Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD)
    Medical condition: Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD)
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2019-003772-39 Sponsor Protocol Number: DEMAND-pilot Start Date*: 2019-12-13
    Sponsor Name:Umeå University
    Full Title: Diet, physical exercise, and metabolic control intervention to reduce the incidence of major neurocognitive disorders among individuals with type 2 diabetes combined with mild neurocognitive impair...
    Medical condition: Type 2 diabetes
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: View results
    EudraCT Number: 2009-016178-33 Sponsor Protocol Number: 1245.25 Start Date*: 2010-11-12
    Sponsor Name:Boehringer Ingelheim B.V.
    Full Title: A Phase III, multicentre, international, randomised, parallel group, double blind cardiovascular safety study of BI 10773 (10 mg and 25 mg administered orally once daily) compared to usual care in ...
    Medical condition: The study will be performed in patients with type 2 diabetes mellitus and high cardiovascular risk who have insufficient glycaemic control despite diet and exercise and are either treatment naïve o...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10067585 Type 2 diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DK (Completed) ES (Completed) BE (Completed) FR (Completed) IT (Completed) HU (Completed) PT (Completed) GB (Completed) AT (Completed) GR (Completed) PL (Completed) EE (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2022-002470-86 Sponsor Protocol Number: 20190218 Start Date*: 2023-05-08
    Sponsor Name:Amgen Inc.
    Full Title: A Phase 2 Randomized, Placebo-controlled, Double-blind, Dose-ranging Study to Evaluate the Efficacy, Safety and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without...
    Medical condition: Overweight and Obesity
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    24.1 10027433 - Metabolism and nutrition disorders 10033307 Overweight PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) HU (Trial now transitioned) CZ (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-003810-18 Sponsor Protocol Number: H9X-MC-GBDE Start Date*: 2012-07-11
    Sponsor Name:Eli Lilly & Company
    Full Title: A Randomized, Open-Label, Parallel-Arm Study Comparing the Effect of Once-Weekly Dulaglutide with Once-Daily Liraglutide in Patients with Type 2 Diabetes (AWARD-6: Assessment of Weekly AdministRati...
    Medical condition: Diabetes Mellitus, Type 2
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10012601 Diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) HU (Completed) DE (Completed) PL (Completed) ES (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2008-006020-53 Sponsor Protocol Number: MIPO3500108 Start Date*: 2009-04-08
    Sponsor Name:Genzyme Europe B.V.
    Full Title: A Prospective Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Mipomersen in Patients With Severe Hypercholesterolemia on a Maximally Tolerated Lipid-Lowering...
    Medical condition: Patients With Severe Hypercholesterolemia on a Maximally Tolerated Lipid-Lowering Regimen and Who are Not on Apheresis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020603 Hypercholesterolaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-001390-88 Sponsor Protocol Number: NT13034 Start Date*: 2012-06-05
    Sponsor Name:Institute for Clinical and Experimental Medicine
    Full Title: Cardioprotective and metabolic effects of metformin in patients with heart failure and diabetes
    Medical condition: type 2 diabetes mellitus, heart failure
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-002803-37 Sponsor Protocol Number: XC001-1001 Start Date*: 2022-01-20
    Sponsor Name:XyloCor Therapeutics, Inc.
    Full Title: A Phase 1/2 Trial of Direct Administration of AdVEGF-All6A+, a Replication Deficient Adenovirus Vector Expressing a cDNA/Genomic Hybrid of Human Vascular Endothelial Growth Factor, to the Ischemic ...
    Medical condition: Angina Pectoris Secondary
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10002383 Angina pectoris PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: View results
    EudraCT Number: 2021-000994-96 Sponsor Protocol Number: 214725 Start Date*: 2021-07-14
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A Phase III, double-blind, randomized, placebo-controlled study to evaluate the safety, reactogenicity and immune response of a single intramuscular dose of unadjuvanted RSV Maternal vaccine, in hi...
    Medical condition: High risk pregnant women (prevention of RSV-associated lower respiratory tract illnesses (LRTIs) in infants)
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: FI (Completed) ES (Temporarily Halted) IT (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2021-001081-38 Sponsor Protocol Number: ARCT-810-03 Start Date*: 2021-12-23
    Sponsor Name:Arcturus Therapeutics, Inc.
    Full Title: Phase 2, Randomized, Double-Blind, Placebo-Controlled, Nested Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ARCT-810 in Adolescent and Adult ...
    Medical condition: Ornithine transcarbamylase deficiency
    Disease: Version SOC Term Classification Code Term Level
    26.0 100000004850 10013373 Disorders of urea cycle metabolism LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) ES (Completed) FR (Completed) SE (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-004774-22 Sponsor Protocol Number: GIP-SEMA Start Date*: 2021-07-08
    Sponsor Name:Herlev Gentofte Hospital
    Full Title: The separate and combined effects of long-term GIP and GLP-1 receptor activation in patients with type 2 diabetes
    Medical condition: Type 2 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10012601 Diabetes mellitus PT
    21.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-001538-41 Sponsor Protocol Number: Start Date*: 2011-06-29
    Sponsor Name:University of Birmingham
    Full Title: The impact of the combination of the GLP-1 analogue liraglutide (Victoza) and laparoscopic adjustable gastric banding (LAGB) on diabetes control
    Medical condition: This trial will investigate the effects of the study treatment arms (gastric band + placebo; gastric band + liraglutide) on diabetes resolution in obese patients.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-002911-24 Sponsor Protocol Number: H9X-MC-GBDG Start Date*: 2013-04-19
    Sponsor Name:Eli Lilly and Company
    Full Title: Protocol H9X-MC-GBDG A Randomized, Parallel-Arm, Double-Blinded Study Comparing the Effect of Once-Weekly Dulaglutide with Placebo in Patients with Type 2 Diabetes Mellitus on Sulfonylurea Therapy...
    Medical condition: Diabetes Mellitus, Type 2
    Disease: Version SOC Term Classification Code Term Level
    16.0 10027433 - Metabolism and nutrition disorders 10012601 Diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) SI (Completed)
    Trial results: View results
    EudraCT Number: 2021-003612-31 Sponsor Protocol Number: I8F-MC-GPGV Start Date*: 2022-08-16
    Sponsor Name:ELI LILLY & COMPANY, LILLY CORPORATE CENTER
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study with an Open-Label Extension Assessing the Efficacy, Safety, and Pharmacokinetics/Pharmacodynamics of Tirzepatide in Pediatric and Adol...
    Medical condition: Type 2 Diabetes Mellitus (T2DM)
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2022-003205-29 Sponsor Protocol Number: CAP2022-1 Start Date*: 2023-02-23
    Sponsor Name:Aphaia Pharma US LLC
    Full Title: A Phase II, randomized, placebo – controlled crossover proof-of-concept study to evaluate efficacy and safety of distal jejunal-release dextrose beads formulation (APHD-012) in subjects with a path...
    Medical condition: Subjects with a pathological Oral Glucose Tolerance Test (OGTT)
    Disease: Version SOC Term Classification Code Term Level
    24.0 100000004861 10065542 Prediabetes LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-004090-29 Sponsor Protocol Number: AVD100521 Start Date*: 2005-02-07
    Sponsor Name:GlaxoSmithKline Research & Development Ltd [...]
    1. GlaxoSmithKline Research & Development Ltd
    2. GlaxoSmithKline R&D
    Full Title: A Phase III, 18 Month, Multicenter, Randomized, Double-Blind, Active-Controlled Clinical Trial to Compare Rosiglitazone versus Glipizide on the Progression of Atherosclerosis in Subjects with Type ...
    Medical condition: atherosclerosis in Type 2 Diabetes Mellitus patients with cardiovascular disease
    Disease: Version SOC Term Classification Code Term Level
    7.1 10003601 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DE (Completed) LV (Completed) IT (Completed) CZ (Completed) GR (Completed) ES (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Apr 05 12:22:05 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA